Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback